The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 19, 2022
Filed:
Mar. 12, 2019
Applicant:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Inventors:
Katalin Kariko, Rydal, PA (US);
Drew Weissman, Wynnewood, PA (US);
Assignee:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01); C07K 14/505 (2006.01); C12N 15/117 (2010.01); C12N 15/67 (2006.01); C07H 21/02 (2006.01); C12Q 1/68 (2018.01); C12N 15/85 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/50 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 38/177 (2013.01); A61K 38/1816 (2013.01); A61K 38/50 (2013.01); A61K 48/005 (2013.01); A61K 48/0041 (2013.01); A61K 48/0075 (2013.01); C07H 21/02 (2013.01); C07K 14/47 (2013.01); C07K 14/4712 (2013.01); C07K 14/505 (2013.01); C12N 15/117 (2013.01); C12N 15/67 (2013.01); C12N 15/85 (2013.01); C12Q 1/68 (2013.01); C12Y 305/04004 (2013.01); A61K 48/00 (2013.01); C12N 2310/17 (2013.01); C12N 2310/33 (2013.01); C12N 2310/3341 (2013.01); C12N 2800/95 (2013.01);
Abstract
This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.